| 15:49 09/01/2012 | Re: RNS- Execution of Lease |
| that says to me sit back relax and watch the profits increase.the future looks good i think that was around 3m gross profit from that harvest alone By cock of the stocks |
|
| 11:18 09/01/2012 | RNS- Execution of Lease |
| DJ Taihua Plc Execution of Lease TIDMTAIH RNS Number : 2139V Taihua Plc 09 January 2012 Taihua plc ("Taihua" or the "Company") Execution of Lease Update on Forsythia Harvest Update on Bian Tong Pian Sales Taihua announces today that it has executed a 20 year lease with Qinyuan Forsythia Farmers' Cooperative in respect of 873 hectares of Forsythia plantation in the Luonan region of the Shanxi province, close to the Company's Traditional Chinese Medicine ("TCM") factory (the "Second Plantation"). As announced on 12 January 2011, Taihua has already leased a significant portion of this plantation (the "First Plantation") and this latest development takes the total area under lease to 1,766 hectares. Pursuant to the terms of the lease of the Second Plantation, Taihua will manage the cultivation and benefit from its harvest. The annual lease cost is RMB1.31m per annum, but it is a term of the Lease that all 20 years are paid in advance (being RMB26.2m). It is therefore agreed that the Company will pay the first instalment of RMB10 million within 15 days of the date of the Lease and a second instalment of RMB16.2 million will be paid by the Company after the formal handover of the land. These payments will represent full and complete settlement of the 20 year term. The Second Plantation consists of 173 hectares of cultivated land and 700 hectares of uncultivated land. The Company expects that the yields and costs associated with Second Plantation will be similar to that of the First Plantation (as set out in the announcement of 12 January 2011). The directors of Taihua can also confirm that the harvest from the First Plantation has been completed and sold. The dry weight harvested was 986 Tonnes and the net of selling tax price was approximately RMB 30.5 per kg. The total overheads are expected to be similar to forecast. Approximately 40% of the sales were for cash and the remaining supplies were sold on 6 month payment terms. Bian Tong Pian The directors of Taihua also confirm that sales of its TCM. Bian Tong Pian totalled 305,600 boxes in the 11 months to the end November 2011 against a total forecast for the 12 months to December 2011 of 330,000 boxes. November was a record month with sales of 48,800 boxes Nicholas Lyth, Chairman, commented "I am pleased to report both the execution of the lease over this second plantation and the maiden harvest from our original plantation. Whilst the quantity of the harvest was less than we had originally hoped for we are pleased that the Forsythia price remains robust. At a total lease cost of RMB26m we believe that this remains an excellent opportunity for the Company. I am thus further encouraged that we have been able to conclude negotiations for the second half of the plantation on very similar terms. We now have a harvest capacity of approximately 2,000 tonnes per annum which we believe makes us a very important player in the supply of Forsythia. Regarding Bian Tong Pian it is particularly encouraging that we are on target to achieve the challenging 2011 target. I believe 2011 represented a significant shift in the focus of Taihua from Active Pharmaceutical Ingredients to TCMs. The Board remain confident that their experience in the Chinese market and their excellent local government relations mean that this is an area that will continue to generate shareholder value." For more information please contact: Nicholas Lyth, Taihua plc +44 (0) 776 990 6686 Katy Mitchell, WH Ireland Limited +44 161 832 2174 This information is provided by RNS The company news service from the London Stock Exchange END MSCUGUCGGUPPGGB (END) Dow Jones Newswires 09-01-12 1115GMT By SpikeyDT |
|
| 18:33 02/11/2011 | Re: MarketWatch |
| Wrong Taihua, Spikey - no relation! By Miles Above |
|
| 13:37 31/10/2011 | MarketWatch |
| PRESS RELEASE http://www.marketwatch.com/story/access-international-further-clarifies-bank-loan-line-of-credit-and-debt-settlement-2011-10-31 Oct. 31, 2011, 9:30 a.m. EDT Access International Further Clarifies Bank Loan, Line of Credit and Debt Settlement CALGARY, Alberta, Oct 31, 2011 (BUSINESS WIRE) -- Access International Education Ltd. (AOE -- TSX Venture Exchange) ("Access" or the "Company") has announced the agreed transfer of title of the 80 mu of land and all concessions as approved by the City of Penglai in addition to the waiver of all rights in the usage of the transferred 80 mu by Sino Canada Jianwen Property Holdings Ltd. ("Jianwen Property"), where Shandong Taihua Investment and Guarantor Co. Ltd. ("Taihua") will agree to assume and take over totally all outstanding bank loans and accrued interests as owed and guaranteed by Jianwen Property and Yuandong Development Co. Ltd. (company owned by Mr. Jian Li personally for the securing of construction financing for the Penglai campus since day one of operation) to the Penglai Rural Credit Union. In the mean time of transfer work being completed, Taihua will agree to act as new guarantor for the said bank debt settlement to the amount of iJPY 39,800,000 RMB ($6,317,460 CAD) which will consist of the outstanding bank debts and accrued interests of iJPY 24,573,311 RMB ($3,854,667 CAD) and of a line of credit of iJPY 15,226,689 RMB ($2,462,793 CAD) to be used for further working capital and the completion of the new Shandong Penglai Zhangyu Helicopter Training Centre project with all agreed parties. Taihua is the owner of Shandong Zhangyu Aviation Training School and is also one of the most successful local investment bankers in Yantai. It owns several teams of small aircrafts and helicopters for commercial and private leisure uses in the province in addition to the vast network of government officials and wealthy businessmen that have been participating in these related up and coming trendy activities in the PRC. For and On Behalf of Access International Education Ltd. (Signed) _____________________________ Chris Gee President & CEO NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS NEWS RELEASE. SOURCE: Access International Education Ltd. Access International Education Ltd. Chris Gee, 403-217-3830 Copyright Business Wire 2011 By SpikeyDT |
|
| 10:29 20/09/2011 | Why isn't Half Year Report RNS on iii? nm |
| Half year results came out yesterday morning but no mention on iii. By drr123 |
|
| 22:15 19/09/2011 | FT-151 per cent increase in traditional Chinese medicine |
| September 19, 2011 8:37 pm By Steve Lodge and Neil Hume Taihua , a Chinese pharmaceutical maker, rose 8.9 per cent to 9.4p after it reported a 151 per cent increase in traditional Chinese medicine sales in the first half of the year. http://www.ft.com/cms/s/0/ccc9bdf4-e2c4-11e0-897a-00144feabdc0.html#ixzz1YQmOm3kk By SpikeyDT |
|
| 18:25 14/04/2011 | Re: Stockpedia......... |
| Great find Spikey More from JT over on advfn-its a pity we dont have that crowd over here! "One thing to bear in mind also Martin is that until EU sales and Injectables kick in, cash flow will be significantly focussed in the last 4 months of each year because of the Forsythia plantations. Also worth considering is the potential profits that could be derived from moving down stream with Forsythia end product. At the time of the plantation announcement 12th January the management indicated a desire to license a new treatment in order to use 50% of the Forsythia raw material produced by the new plantation. "Taihua's strategy is to develop TCMs that will utilise output from the plantation and thus ultimately sell the TCM as well as the TCM raw material. In discussions with the China Academy of Chinese Medical Sciences it has identified a low-side effect, Forsythia-based TCM currently under their development. It is Taihua's intention to licence this product once it is fully developed. When this product is in full production it is anticipated that it will require approximately 50% of the total harvest of Forsythia." http://www.advfn.com/p.php?pid=nmona&article=45988418&symbol=TAIH Lets remind ourselves of the price that Forsythia oil commands in the market today, let alone a finished treatment (see various post links): http://www.advfn.com/cmn/fbb/thread.php3?id=17867062&from=5763 imo the Taihua management have an embarrassment of options now in which to drive profits and a cash chest to facilitate that goal. That's a nice position to be in. Options: Double the Forsythia Plantation Launch Forsythia based product licensed from Chinese Government Bring own Yew tree plantation on line to save on raw material costs Paclitaxel EU distribution deal Paclitaxel Injectables in EU Paclitaxel China distribution deals Paclitaxel Injectables in China Paclitaxel distribution deals in other 'nonregulated' parts of the world HH EU distribution deal HH China Distribution enhancement deals HH injectables in EU and China Further large distribution deals for TCM's in China New TCM products Outsourcing injectables for big Pharma's at low cost As I say, it's a nice situation to be in." By getemout |
|
| 13:33 14/04/2011 | Stockpedia......... |
| Three Bombed out Chinese AIM Stocks - Ben Graham Bargains or Value Traps? Thursday, Apr 14 2011 by Edward Croft Back in 2006-2007, many private investors had it easy. The markets were on a tear and UK investors were benefiting from a boom in new flotations on AIM. Amongst them were a ream of Chinese listings which were attracted to AIM in order to raise growth capital. These included the glamour stock Renesola (LON:SOLA) , a solar wafer company which proceeded to sextuple over about 18 months amongst much decadent howling from private investors on the bulletin boards. Of course it couldn't last, and Renesola, as well as most of the other Chinese stocks, crashed during the credit crunch. Picking up the pieces today, there are a few Chinese AIM stocks that have recovered somewhat, with some such as Asian Citrus (LON:ACHL) posting very strong gains and moving to new highs, but there are also many that have remained bombed out predominantly on size, accounting and cashflow concerns. The worry that many investors have is that they just don't trust these companies, and don't trust the companies' accounting practices. As a result these companies now trade on completely derisory ratings - to such an extent that they are now appearing on our screens as selling for less than their liquidation value. Ben Graham, the famous value investor and tutor of Warren Buffett, was the ultimate contrarian investor and loved derisory ratings. He was the investment world's first ever 'quant', running his investment fund for many years almost purely based on a statistical strategy that looked to buy bombed out stocks for less than their liquidation value. Graham wasn't shy of investing where others feared to tread as he believed that in a well spread portfolio any individual bankruptcy risks could be diversified away. Holding anywhere from 30 to 100 stocks, he found the investment returns that resulted to be 'more than satisfactory', with his Graham-Newman partnership returning 17% per year. If you take a Graham approach to the market, you look for companies that are selling for less than what investors would receive in the worst possible scenario; a liquidation. In this scenario, there's really little point the companies remaining on the market as investors could just liquidate and make a profit. Knowing that in a firesale companies might not get full value for their assets he used an extremely cautious calculation to value them. In his 'Net Net Working Capital' approach would ignore all fixed and intangible assets (property, brands etc) and focus on the liquid assets that could be sold quickly, i.e. the cash, stocks and debtors net of all creditors. Graham liked to find companies that sold for a price of less than .7 times this figure to give himself a significant margin of safety. While there are still occasionally companies that qualify for this margin of safety these days most investors allow higher multiple of up to 1.5 times due to their rarity. If you screen the market on these attributes you find three Chinese AIM stocks come up on your screen amongst the cheapest in the market. Some of these used to be popular amongst private investors but which now can only be described as long term dogs from a performance perspective. The following figures are from Sharescope and Sharelock Holmes. RCG (LON:RCG) , a biometric and RFID specialist, which sells at a market cap of £65m, having net current assets of £167m incorporating cash of £25m - Price/net net working capital ratio of 0.7. Geong (LON:GNG) , a company selling enterprise CRM solutions, selling at a market cap of £12.6m, having net current assets of £16.3m including cash of £6.4m and no debt - Price/NNWC ratio of 1.12. Taihua (LON:TAIH) , a company cultivating a Yew extract Paclitaxel needed for the treatment of cancer, selling at a market cap of £11.2m, having net current assets of £10.5m which includes cash of almost £8m and no debt. Price/NNWC rat By SpikeyDT |
|
| 10:18 04/03/2011 | TU-Some good news on its way soon. |
| Off advfn; All credit to DP for his post yesterday.... duplicate book - 3 Mar'11 - 10:48 - 5917 of 5927 The trading update will be out in a week or so. Its not quite ready yet as it is going to reflect the revenues regarding the Distributor deal for the TCM signed in November, and the implications regarding the purchase of the lease on the Forsythia plantation, so we should get an indication of the forward earnings potential as well as recent trading performance. Brokers Note is to be released at, or about, the same time. We can also expect to get an update on another issue that is close to all our hearts, (though not necessarily with the TU). By getemout |
|
| 23:12 13/01/2011 | Re: More to the news than meets the eye? |
| broker note also been worked on.there is huge support at this level happy to add on any fall.worth mid 20s now imho the tcm's now look the driving force By cock of the stocks |
|
| 12:50 13/01/2011 | More to the news than meets the eye? |
| I've held these for 4 yrs now, and added 5 times. So you could say im biased, but I believe we have now embarked on a new life for this company. They seem to be issuing decent news flow, on a more regular basis, and I now look forward to their expected update, hopefully in the next few weeks or so. Re yesterdays news, this could be of serious positive impact-as per JT's post on advfn yesterday; "http://www.academicjournals.org/jmpr/PDF/pdf2010/18July/Wen%20et%20al.pdf RESULTS AND DISCUSSION Although, many efforts have been made during these years, there are no licensed vaccines available for preventing respiratory viral infections other than influenza. Recently, many countries have been paying more attention to search for anti-virus agents among Chinese medicinal herbs. The F. suspensa is a traditional Chinese medicinal herb. Its pharmacological effects such as antipyretic, antidotal and anti-inflammatory effect were well documented (Zhang et al., 2000). In the present study, we demonstrated that FSE was an effective anti-virus agent, which could have marked respiratory H1N1 virus effect in vitro. Analysis of H1N1 virus titers showed the cells in all quadrupled wells treated with H1N1 virus at titer of 10-1-10-5 appeared 100% CPE. The cells treated with H1N1 virus at titer of 10-6, the cells in two wells appeared 100% CPE while the others appeared 50% CPE. According to the detection of the toxicity of FSE, it was indicated that the cells co-cultured with FSE at concentrations from 1:2 to 1:256 mg/mL appeared CPE of different degrees, while the cells co-cultured with FSE at concentrations from 1:512 to 1:8192 mg/mL displayed no CPE. The 50% toxic concentration was 1:256 mg/mL according to Reed-Muench method. Data presented in Table 1 also indicated that FSE had no toxicity to MDCK cells at concentrations from 1:512 to 1:1024 mg/mL and the cells co-cultured with 1 mg/mL DMSO showed no CPE, indicating that DMSO at this concentration range had no toxicity to MDCK cells. We also evaluated the anti-H1N1 virus effect of FSE. Data presented in Tables 2 - 3 implied that 1:512 to 1:8192 mg/mL FSE showed various protective effects on MDCK cells and the effect was decreased with the increased dilution. There was an obvious correlation between them with the most effective concentrations from 1:526 to 1:2048 mg/mL. The minimal effective inhibitory concentration was 1:8192. The value of A600 obtained using crystal violet staining showed that decreased with the increased dilution. Conclusion In conclusion, the present study indicated that FSE may have a significant antivirus effect on acute respiratory tract infections with H1N1 virus infection. This could be useful for further antivirus research on acute respiratory tract infections. However, further study is needed to clarify its antivirus mechanism on H1N1 virus, and its anti - virus effects on other viruses." By getemout |
|
| 10:01 13/01/2011 | Finally on the move in the right direction. |
| Onwards & upwards. By Max1977 |
|
| 16:09 08/12/2010 | Re: GMP Update |
| http://www.stockmarketwire.com/display/?id=4029163§ionId=standardNews By carlsmillie |
|
| 15:11 08/12/2010 | Re: GMP Update |
| DJ Taihua Gets Chinese Good Manufacturing Practice Certificate LONDON (Dow Jones)-- Taihua PLC (TAIH.LN), a firm engaged in the development, production, distribution and sale of active pharmaceutical ingredients, said Wednesday following a recent audit of its facilities it has achieved Chinese Good Manufacturing Practice in respect of its Traditional Chinese Medicines. MAIN FACTS: -Certificate has been issued by the Chinese State Food and Drug Administration for a further five years. -Shares at 1505 GMT up 0.50 pence or 4.88% at 10.75 pence. -By Tapan Panchal, Dow Jones Newswires. Tel +44(0)207-842 9448, tapan.panchal@dowjones.com (END) Dow Jones Newswires December 08, 2010 10:09 ET (15:09 GMT) Copyright (c) 2010 Dow Jones & Company, Inc. By carlsmillie |
|
| 15:02 08/12/2010 | GMP Update |
| DJ Taihua Plc GMP Update TIDMTAIH RNS Number : 6148X Taihua Plc 08 December 2010 ? Taihua plc ("Taihua" or the "Company") GMP Update Tahua confirms that following a recent audit of the Company's facilities it has once again achieved Chinese Good Manufacturing Practice ("GMP") in respect of its Traditional Chinese Medicines. This GMP certificate has been issued by the Chinese State Food and Drug Administration for a further 5 years. Nicholas Lyth, Chairman of Taihua plc commented "Following the Chinese Government's decision to temporarily suspend the operations of a large number of Traditional Chinese Medicine manufacturers in 2009 it is particularly pleasing for Taihua to have a renewed GMP for this range of products. We believe that the Chinese Government will continue to vigorously police the TCM manufacturers. This presents an opportunity for those companies like Taihua who have the necessary investment, training and procedures to ensure supply of high quality product into the marketplace." For more information please contact: +---------------------------------+---------------------------------+ | Nicholas Lyth, Taihua plc | 0776 990 6686 | +---------------------------------+---------------------------------+ | Katy Mitchell, WH Ireland | +44 161 832 2174 | | Limited | | +---------------------------------+---------------------------------+ This information is provided by RNS The company news service from the London Stock Exchange MSCTPBITMBAMBPM (END) Dow Jones Newswires 08-12-10 1500GMT By carlsmillie |
|